美卡培格司亭预防局部晚期鼻咽癌化疗所致中性粒细胞减少症：一项前瞻性II期临床研究。
Mecapegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia in locally advanced nasopharyngeal carcinoma: A prospective phase II clinical study.
作者信息
Jin Qifeng, Hua Yonghong, Jin Ting, Wang Lei, Tao Changjuan, Huang Shuang, Qin Weifeng, Chen Xiaozhong
机构信息
Department of Head and Neck Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
出版信息
Head Neck. 2025 Jan;47(1):263-268. doi: 10.1002/hed.27897. Epub 2024 Aug 11.
BACKGROUND
Induction chemotherapy of docetaxel plus cisplatin (TP) is myelosuppressive, leading to severe neutropenia and febrile neutropenia (FN). Herein, we aimed to investigate the efficacy and safety of mecapegfilgrastim in the prevention of neutropenia in patients with locally advanced nasopharyngeal carcinoma who received the TP regimen.
METHODS
A total of 30 treatment-naive patients with locally advanced nasopharyngeal carcinoma were included in this study. Mecapegfilgrastim 6 mg was injected 24-48 h after the completion of induction chemotherapy with the TP regimen.
RESULTS
The incidence of grade ≥3 neutropenia during the three induction chemotherapy cycles was 6.7% (95% CI, 0.8%-22.1%). In the first cycle of chemotherapy, the incidence of grade ≥3 neutropenia was 3.3% (95% CI, 0.1%-17.2%). No FN or antibiotic usage was reported. All 30 patients completed the induction chemotherapy cycles.
CONCLUSION
Mecapegfilgrastim effectively reduced the incidence of chemotherapy-induced neutropenia and FN in patients with locally advanced nasopharyngeal carcinoma.
背景
多西他赛联合顺铂（TP）的诱导化疗具有骨髓抑制作用，可导致严重的中性粒细胞减少和发热性中性粒细胞减少（FN）。在此，我们旨在研究美培非格司亭预防接受TP方案治疗的局部晚期鼻咽癌患者中性粒细胞减少的疗效和安全性。
方法
本研究共纳入30例初治的局部晚期鼻咽癌患者。在TP方案诱导化疗结束后24 - 48小时注射6毫克美培非格司亭。
结果
在三个诱导化疗周期中，≥3级中性粒细胞减少的发生率为6.7%（95%CI，0.8% - 22.1%）。在化疗的第一个周期中，≥3级中性粒细胞减少的发生率为3.3%（95%CI，0.1% - 17.2%）。未报告有FN或使用抗生素的情况。所有30例患者均完成了诱导化疗周期。
结论
美培非格司亭有效降低了局部晚期鼻咽癌患者化疗诱导的中性粒细胞减少和FN的发生率。
Zotero 插件